Showing 3571-3580 of 5154 results for "".
- China's NMPA Accepts Akeso’s NDA for Ebdarokimab in Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/chinas-nmpa-accepts-akesos-nda-for-ebdarokimab-in-moderate-to-severe-plaque-psoriasis/2461958/Akeso Inc.’s New Drug Application (NDA) for its fully human IgG1monoclonal antibody ebdarokimab (IL-12/lL-23, AK101) for the treatment of adults with moderate-to-severe plaque psoriasis has been accepted by the National Center for Drug Evaluation of the State Drug Administration of the
- Verrica Pharmaceuticals Update: Company Announces First Sale of YCANTH to FFF Enterpriseshttps://practicaldermatology.com/news/verrica-pharmaceuticals-update-company-announces-first-sale-of-ycanth-to-fff-enterprises/2461957/Verrica Pharmaceuticals Inc. announced the first commercial sale of YCANTH to its exclusive distributor, FFF Enterprises Inc. (FFF). “As one of the nation’s most trusted specialty pharmaceutical distributors, FFF is well positioned to help Verrica introduce YCANTH&trad
- New Platform May Help Determine Which Melanoma Patients Will Respond to Immunotherapyhttps://practicaldermatology.com/news/new-platform-may-help-determine-which-melanoma-patients-will-respond-to-immunotherapy/2461949/A new approach that integrates a minimally invasive, painless microneedle platform may help monitor protein biomarkers in responses to a combination immunotherapy against melanoma. The platform is capable of absorbing the cell-surrounding, biomarker-containing fluid from deeper layers o
- Immunotherapy Drug Combo Helps Extend Progression-Free Survival in Metastatic Melanomahttps://practicaldermatology.com/news/immunotherapy-drug-combo-helps-extend-progression-free-survival-in-metastatic-melanoma/2461940/Combining two immune checkpoint inhibitors helps overcome resistance to prior PD-1 therapy in patients with metastatic melanoma, a new study shows. The combination of ipilimumab and nivolumab showed a longer progression-free survival, but also a greater overall response rate t
- Wristbands May Be Home to E. coli, Staphhttps://practicaldermatology.com/news/wristbands-may-be-home-to-e-coli-staphylococcus/2461937/Common wristbands can be ‘hotbed’ for harmful bacteria including E. coli, staphylococcus, according to new research. Researchers from Florida Atlantic University’s Charles E. Schmidt Colleg
- New Report Highlights Challenges in Evaluating Biosimilarshttps://practicaldermatology.com/news/new-report-highlights-challenges-in-evaluating-biosimilars/2461933/New research provides an overview of gaps and challenges in the value assessment of biosimilars and identifies potential approaches to address them. The report, “
- Found: 135 New Melanin Genes Responsible for Pigmentationhttps://practicaldermatology.com/news/found-135-new-melanin-genes-responsible-for-pigmentation/2461927/Researchers have discovered 135 new genes associated with pigmentation. “To understand what actually causes different amounts of melanin to be produced, we used a technology called CRISPR-Cas9 to genetically engineer cells,” explains study author
- PSA: Vets Warn That Minoxidil May Be Deadly to Petshttps://practicaldermatology.com/news/vets-warn-that-minoxidil-may-be-deadly-to-pets/2461917/Products like Rogaine, which contain minoxidil, can be very dangerous to animals, warn toxicology experts at Pet Poison Helpline. “Cats are particularly sensitive to this medication, and any exposure can result in severe poisoning and potentially death,” says Renee
- Evolus Rolls Out New Branding for Jeuveauhttps://practicaldermatology.com/news/evolus-rolls-out-new-branding-for-jeuveau/2461913/Evolus, Inc. is unveiling its new branding for Jeuveau (prabotulinumtoxinA-xvfs). The new Jeuveau imagery reflects today’s consumers, many of whom are millennials and younger. The “Jeuveau, You See Me” marketing campaign uses inclusive messaging to encourage
- Replimune, Incyte Enter Into Clinical Trial Collaboration And Supply Agreement To Evaluate RP1 and INCB99280 in CSCChttps://practicaldermatology.com/news/replimune-incyte-enter-into-clinical-trial-collaboration-and-supply-agreement-to-evaluate-rp1-and-incb99280-in-cscc/2461908/Replimune Group, Inc. and Incyte are collaborating to a study RP1 in combination with INCB99280, Incyte’s small molecule oral PD-L1 inhibitor, in cutaneous squamous cell carcinoma (CSCC) and in other cancer types,